The PanTHERA Difference

Reducing Cryopreservation Damage

PanTHERA’s ice recrystallization inhibitors (IRIs) increase overall post-thaw cell recovery and quality by reducing damage throughout the cryopreservation process. Our IRIs are proven to be more effective in comparison to commercially  available cryopreservation solutions.

Reducing Toxicity of Conventional Cryoprotectants

Our IRIs permit the use of lower amounts of conventional Cryoprotective Agents (CPA) resulting in higher post-thaw viability and recovery.  CPA compounds are toxic and can damage the cells they are meant to preserve. By adding IRIs to existing cryopreservation solutions, we significantly reduce the cell damage resulting from the toxic effects of glycerol, dimethyl sulfoxide (DMSO) and hydroxyethyl starch (HES), the primary CPAs used in cell preservation.

Reducing Damage from Transient Warming

PanTHERA’s product reduces damage from transient warming occurring during cell banking and shipping. Transient warming is a significant concern as it can negatively affect cells and their ability to function properly. PanTHERA’s IRIs protect cells from the damage associate with temperature fluctuations during cryostorage leading to improved post-thaw viability and recovery as well as enhanced functionality.

Improving the Stability of Frozen Cells

PanTHERA improves the stability of frozen cells thus permitting storage over a broader range of temperatures. Liquid nitrogen storage systems can be prohibitively expensive to operate.  Since IRIs enable higher sub-zero storage of cryopreserved samples, they can significantly reduce the cost of banking cell inventories. Higher sub-zero storage simplifies the transportation of cells and extended storage within conventional freezers with no need for liquid nitrogen or use of special shipping containers.

pt-hp-desktop-alt-section

The PanTHERA Difference

Reducing Cryopreservation Damage

PanTHERA’s ice recrystallization inhibitors (IRIs) increase overall post-thaw cell recovery and quality by reducing damage throughout the cryopreservation process. Our IRIs are proven to be more effective in comparison to commercially  available cryopreservation solutions.

Reducing Toxicity of Conventional Cryoprotectants

Our IRIs permit the use of lower amounts of conventional Cryoprotective Agents (CPA) resulting in higher post-thaw viability and recovery.  CPA compounds are toxic and can damage the cells they are meant to preserve. By adding IRIs to existing cryopreservation solutions, we significantly reduce the cell damage resulting from the toxic effects of glycerol, dimethyl sulfoxide (DMSO) and hydroxyethyl starch (HES), the primary CPAs used in cell preservation.

Reducing Damage from Transient Warming

PanTHERA’s product reduces damage from transient warming occurring during cell banking and shipping. Transient warming is a significant concern as it can negatively affect cells and their ability to function properly. PanTHERA’s IRIs protect cells from the damage associate with temperature fluctuations during cryostorage leading to improved post-thaw viability and recovery as well as enhanced functionality.

Improving the Stability of Frozen Cells

PanTHERA improves the stability of frozen cells thus permitting storage over a broader range of temperatures. Liquid nitrogen storage systems can be prohibitively expensive to operate.  Since IRIs enable higher sub-zero storage of cryopreserved samples, they can significantly reduce the cost of banking cell inventories. Higher sub-zero storage simplifies the transportation of cells and extended storage within conventional freezers with no need for liquid nitrogen or use of special shipping containers.

pt-hp-mobile-alt-section

Benefits

Improved Performance

PanTHERA’s IRIs improve post-thaw recovery and functionality of cells which can positively impact research and potentially enhance clinical patient outcomes. In addition to its use in stabilizing cell and gene therapies for medical applications, our IRI technology can be used across several areas that include assisted reproductive technologies, animal and aquaculture husbandry, cell-based diagnostics, and biopharmaceutical production. Our novel IRI technology opens numerous opportunities for scientists and laboratories to explore.

Significant Cost Reductions

PanTHERA IRI technology reduces operational costs including logistics and shipping. In certain applications, IRIs allow for higher sub-zero storage of samples reducing the cost of cell banking inventories.

pt-hp-desktop-benefits-section

Benefits

Improved Performance

PanTHERAs IRI’s improve post-thaw recovery and functionality of cells which can positively impact research and potentially enhance clinical patient outcomes. In addition to its use in stabilizing cell and gene therapies for medical applications, our IRI technology can be used across several areas that include assisted reproductive technologies, animal and aquaculture husbandry, cell-based diagnostics, and biopharmaceutical production. Our novel IRI technology opens numerous opportunities for scientists and laboratories to explore.

Significant Cost Reductions

PanTHERA IRI technology reduces operational costs including logistics and shipping. In certain applications, IRIs allow for higher sub-zero storage of samples reducing the cost of cell banking inventories.

pt-hp-mobile-benefits-section

Applications

PanTHERA’s technology to control ice recrystallization is a platform technology that can be applied across multiple application areas. The following provides insight into some of the initial applications of our novel technology.

  • Research and development
  • Gene and cell therapy products
  • Organ, tissue, and blood banking
  • Biomanufacturing industry (such as viral vectors, oncolytic virus, recombinant proteins, vaccines)
  • Assisted reproductive technologies
  • Animal and aquaculture-specific breeding and preservation
pt-hp-desktop-applications-section

Applications

PanTHERA’s technology to control ice recrystallization is a platform technology that can be applied across multiple application areas. The following provides insight into some of the initial applications of our novel technology.

  • Research and development
  • Gene and cell therapy products
  • Organ, tissue, and blood banking
  • Biomanufacturing industry (such as viral vectors, oncolytic virus, recombinant proteins, vaccines)
  • Assisted reproductive technologies
  • Animal and aquaculture-specific breeding and preservation
pt-hp-mobile-applications-section
Learn More About Our Science & Innovation

News & Events

PanTHERA Feature: David Lewandowski, Director of Business Development at AmplifyBio

By Elizabeth Tan / 16 July 2024
PanTHERA CryoSolutions had the opportunity to sit down with David Lewandowski, presently Director of Business Development, at AmplifyBio, to chat...
Read More
PanTHERA Feature: David Lewandowski, Director of Business Development at AmplifyBio

Scientist Feature: Dr. Esme Dijke, Director at the Histocompatibility Laboratory and Assistant Professor for Lab Medicine and Pathology.

By Elizabeth Tan / 29 May 2024
PanTHERA had an incredible opportunity to chat with Dr. Esme Dijke, Director at the Histocompatibility Laboratory and Assistant Professor for...
Read More
Scientist Feature: Dr. Esme Dijke, Director at the Histocompatibility Laboratory and Assistant Professor for Lab Medicine and Pathology.

Unlocking Quality: Understanding GMP Grade Products

By Elizabeth Tan / 14 April 2024
Ensuring the safety and efficacy of pharmaceuticals, biotechnology products, and certain food and dietary supplements is paramount. This commitment to...
Read More
Unlocking Quality: Understanding GMP Grade Products

Cryopreservation: A Key to Conserving Biodiversity

By Elizabeth Tan / 29 February 2024
In the face of unprecedented environmental changes and human activities, the preservation of biodiversity has become a global imperative. Biodiversity,...
Read More
Cryopreservation: A Key to Conserving Biodiversity

Scientist Feature: Dr. Anna Jezierski, Research Officer with the Human Health Therapeutics Research Centre at the NRC

By Elizabeth Tan / 19 December 2023
PanTHERA CryoSolutions sat down with Dr. Anna Jezierski to hear from her about her work and how our novel Ice...
Read More
Scientist Feature: Dr. Anna Jezierski, Research Officer with the Human Health Therapeutics Research Centre at the NRC

Revolutionizing Agriculture: The Crucial Role of Cryopreservation

By Elizabeth Tan / 23 November 2023
Revolutionizing Agriculture: The Crucial Role of Cryopreservation In the ever-evolving landscape of agriculture, advancements in technology continue to shape the...
Read More
Revolutionizing Agriculture: The Crucial Role of Cryopreservation

The Vital Role of Ice Recrystallization Inhibitors in Cold Chain Management

By Elizabeth Tan / 23 November 2023
The Vital Role of Ice Recrystallization Inhibitors in Cold Chain Management In the world of logistics and supply chain management,...
Read More
The Vital Role of Ice Recrystallization Inhibitors in Cold Chain Management

Ice Recrystallization Inhibitors: A Promising Breakthrough in Cryopreservation

By Elizabeth Tan / 26 July 2023
Ice Recrystallization Inhibitors: A Promising Breakthrough in Cryopreservation Cryopreservation, the process of preserving biological materials at extremely low temperatures, is...
Read More
Ice Recrystallization Inhibitors: A Promising Breakthrough in Cryopreservation

PanTHERA CryoSolutions Press Coverage

By Elizabeth Tan / 21 July 2023
PanTHERA CryoSolutions is honoured to be featured in various news outlets across the country. These articles are a testament to...
Read More
PanTHERA CryoSolutions Press Coverage

GlycoNet and PanTHERA CryoSolutions’ Journey: From Bench to Bedside

By Elizabeth Tan / 16 July 2023
GlycoNet and PanTHERA CryoSolutions’ Journey: From Bench to Bedside PanTHERA CryoSolutions is a Canadian corporation that designs and manufactures cryopreservation...
Read More
GlycoNet and PanTHERA CryoSolutions’ Journey: From Bench to Bedside